Sysmex

Skip Navigation

SearchMenu

Management Policies

Message from the Chairman and CEO

Net sales and operating profit increased year on year, boosted by solid performance in Japan and overseas.

代表取締役会長兼社長 家次 恒

February 2018

家次 恒

Net sales and operating profit rose, owing to generally robust business performance in all geographic regions.

 

Profit attributable to owners of the parent was down, mainly reflecting the temporary impact of the revision of a tax treaty with Germany in the previous fiscal year.

 

During the first nine months of the fiscal year ending March 31, 2018, net sales and operating profit increased, due to generally firm business performance in all geographic regions. However, profit attributable to owners of the parent was down year on year, mainly reflecting the temporary impact of the revision of a tax treaty with Germany in the previous fiscal year. Net sales rose 12.0% year on year, and operating profit increased 13.8%, while profit attributable to owners of the parent fell 4.4%. At the exchange rates prevailing one year earlier, net sales would have been up 7.0% and operating profit up 9.7%.

In Japan, sales rose due to higher sales of reagents in the hematology1, hemostasis and immunochemistry fields. Overseas, sales grew thanks to higher sales of reagents, centered on the hematology and hemostasis fields, due expansion of the installed instrument base. As a result, the Group’s overseas sales ratio was 84.1%.

We maintain unchanged the consolidated performance forecast we announced in November 2017 for the full fiscal year ending March 31, 2018.*

Sysmex has begun conducting collaborative research with the National Cancer Center, JVCKENWOOD Corporation and Daiichi Sankyo Co., Ltd., targeting microparticles called exosomes, which are released from tissues, with the aim of raising the quality of cancer diagnosis and treatment. The research, to detect specific protein-expressing exosomes, is expected to provide a new option to help make decisions for cancer therapy and evaluate drug treatment outcomes from blood, in addition to the current tumor tissue sampling approach.

 

* These forecasts are based on information available as of the date of this release. Actual results may differ materially from these forecasts due to various unforeseen factors and future events. 

 

 

1 Hematology field: The field of in vitro diagnostics that determines whether precise testing is necessary by analyzing the number, type and size of red, white and other blood cells.


Back to "Management Policies"